Charlottesville
-
All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzheimer’s drug R&D
Acumen Pharmaceuticals’ IPO raised $160 million to fund clinical development of its Alzheimer’s disease drug candidate. Though that drug goes after the same target as Biogen’s recently approved Aduhelm, Acumen says its antibody has potential dosing and safety advantages.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
InSpark’s app spots patterns to help diabetes patients avoid hospitalization
The app is based on technology licensed from the University of Virginia Licensing and Ventures Group.
-
Devices & Diagnostics, Hospitals, Startups
Diagnostic to assess clotting disorders in surgery raises new capital
A medical device company has raised nearly $1.3 million to advance a diagnostic to detect […]